A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer

NCT06182761 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Sunvozertinib combination with Anlotinib

Sponsor

Shanghai Zhongshan Hospital